A Multi-center, Open-label, Single-arm, Phase IV Clinical Trial to Evaluate the Preference Regarding Convenience of Medication, Efficacy and Safety After Switching to SUGAMET®XR Tablet 5/1000mg in Patients With Type 2 Diabetes and Renal Diseases

NCT04653779 Phase 4 UNKNOWN

Multi-center, open-label, single arm study to Evaluate the preference regarding convenience of medication, efficacy and safety of Sugamet XR tab. 5/1000mg in patients with Type 2 diabetes and renal diseases

Details

Lead sponsor	Dong-A ST Co., Ltd.
Phase	Phase 4
Status	UNKNOWN
Enrolment	54
Start date	2020-12
Completion	2021-07

Conditions

• Diabetes Mellitus, Type 2
• Renal Disease
• Diabetes Mellitus
• Metabolic Disease
• Endocrine System Diseases

Interventions

• Evogliptin 5mg/Metformin 1000mg

Primary outcomes

• The preference regarding convenience of medication — 12 weeks
  Looking back on the experience of participating in the study, which would you prefer, any of the existing DPP-4 inhibitor/metformin 1000mg sustained-release combination drug or the SugarMet® sustained-release tablet 5/1000mg?

Countries

South Korea